Mar 19, 2018   SOURCE: PR NewsWire

Global Oral Proteins and Peptides Market Expected to Reach $8,233 Million by 2028 - Allied Market Research

PORTLAND, Oregon and PUNE, India, March 19, 2018 /PRNewswire/ --

According to a new report published by Allied Market Research, titled, "Oral Proteins and Peptides Market by Drug Type and Application: Global Opportunity Analysis and Industry Forecast, 2022-2028 [https://www.alliedmarketresearch.com/oral-proteins-peptides-market ], " the global oral proteins and peptides market was valued at $643 million in 2016, and is projected to reach $8,233 million by 2023, growing at a CAGR of 11.7% from 2022 to 2028. The linaclotide drug type segment occupied the highest market share of the market in 2016.

(Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg )

Therapeutic proteins and peptides are an important class of drugs, which serve patients in need of novel therapies. Approved oral proteins and peptides drugs are indicated to treat a wide array of clinical indications, including diabetes, gastric & metabolic disorders, and hormonal disorders.

Request for Sample Report at: https://www.alliedmarketresearch.com/request-sample/378

The major factors that drive the growth of the global oral proteins and peptides market include increase in collaborative efforts between pharmaceutical companies, surge in prevalence of chronic conditions, increase in elderly population, and rise in awareness & preference among populace for oral proteins and peptide-based drugs.

However, high cost associated with drug development and low bioavailability of these drugs impede the market growth. Conversely, increase in novel indications for known oral protein therapeutics, high R&D investment by pharmaceutical companies in oral proteins & peptides drugs, and rise in purchasing power in the emerging markets are anticipated to provide lucrative opportunities for the manufacturers in this industry.

The gastric & digestive disorders application generated the highest revenue in 2016, and is anticipated to continue this trend in the future. This is attributed to the approval and high adoption of oral proteins and peptide drugsLINZESS (Allergan, Inc.) and TRULANCE (Synergy Pharmaceuticals, Inc.). The diabetes application is anticipated to grow at the highest CAGR of 13.4% from 2022 to 2028.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/378

The U.S. held the highest market share in 2016, owing to high prevalence rate of chronic diseases, rise in adoption of these drugs, and increase in awareness about oral protein and peptide therapeutics. The rest of the world is expected to grow owing to rapid industrialization, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.

Key Findings of the Oral Proteins and Peptides Market: 

        
        - The insulin drug type segment is anticipated to grow at the highest CAGR from 2022
          to 2028
        - The gastric & digestive disorder application segment is anticipated to occupy the
          largest share in the oral proteins and peptides market
        - The diabetes segment is expected to witness the highest growth rate during the
          forecast period
        - The U.S. dominated the oral proteins and peptides market, and is projected to grow at
          a CAGR of 11.7%

The report provides extensive competitive analysis and profiles of key market players, such as Allergan plc, AstraZeneca plc, Biocon Limited, Chiasma, Inc., Proxima Concepts Limited (Diabetology Ltd.), Generex Biotechnology Corp., Novo Nordisk A/S, Synergy Pharmaceuticals Inc., and Tarsa Therapeutics Inc. Other players (profiles not included in the report) in the value chain analysis include Sanofi S.A., F. Hoffmann-La Roche AG, Synthetic Biologics, Inc., Hovione Limited, and Novartis International AG.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. 

        

        Contact: 
        Shriram Dighe 
        5933 NE Win Sivers Drive 
        #205, Portland, OR 97220 
        United States 
        Toll Free: +1-800-792-5285 
        UK: +44-845-528-1300 
        Hong Kong: +852-301-84916 
        India (Pune): +91-20-66346060 
        Fax: +1   855   550-5975 
        help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com 


    Photo: 
    https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

SOURCE Allied Market Research